MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Rapamycin

CAS No. : 53123-88-9

MCE 國際站：Rapamycin

產(chǎn)品活性：Rapamycin (Sirolimus) 是一種有效且特異性的 mTOR 抑制劑，作用于 HEK293 細(xì)胞，抑制 mTOR，IC₅₀ 為 0.1 nM。Rapamycin 與 FKBP12 結(jié)合且抑制 mTORC1。Rapamycin 還是一種自噬 (autophagy) 激活劑，免疫抑制劑。

研究領(lǐng)域：PI3K/Akt/mTOR  |  Autophagy  |  Apoptosis  |  Immunology/Inflammation  |  Anti-infection  |  Metabolic Enzyme/Protease

作用靶點：mTOR  |  FKBP  |  Fungal  |  Autophagy  |  Endogenous Metabolite  |  Antibiotic  |  Bacterial

結(jié)構(gòu)分類：抗生素  |  疾病研究  |  抗炎/免疫調(diào)劑  |  抗生素  |  大環(huán)內(nèi)脂類  |  結(jié)構(gòu)分類

In Vitro: Rapamycin (12.5-100 nM; 24 hours) treatment exerts modest inhibitory effect on lung cancer cell proliferation in a dose-dependent manner in all cell lines (A549, SPC-A-1, 95D and NCI-H446 cells) tested, achieving about 30-40% reduction in cell proliferation at 100 nM vs. ~10% reduction at 12.5 nM.
Lung cancer cell line 95D cells are exposed to Rapamycin (10 nM, 20 nM) and RP-56976 (1 nM, 10 nM) alone or in combination (Rapamycin 20 nM+ RP-56976 10 nM). After 24 hours exposure to Rapamycin or RP-56976 alone does not significantly alter the level of expression or phosphorylation of ERK1/2, whereas cells treated with the combination of Rapamycin with RP-56976 exhibit a marked reduction in the phosphorylation levels of ERK1/2.

In Vivo: Rapamycin (2.0 mg/kg; intraperitoneal injection; every other day; 28 days) alone has a moderate inhibitory effect. However, the combination of Metformin and Rapamycin exerts a significantly increased inhibition of tumor growth compared with the control group, the Rapamycin monotherapy group and the Metformin monotherapy group.

相關(guān)產(chǎn)品：Covalent Screening Library Plus  |  Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  Metabolism/Protease Compound Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Human Endogenous Metabolite Compound Library  |  Peptidomimetic Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antioxidant Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Macrocyclic Compound Library  |  Lipid Compound Library  |  Oxygen Sensing Compound Library  |  Antifungal Compound Library  |  Antibacterial Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Chemical Probe Library  |  Glutamine Metabolism Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Antibiotics Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Microbial Metabolite Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Lipid Metabolism Compound Library   |  Glucose Metabolism Compound Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Children’s Drug Library  |  Anti-Cancer Natural Product Library  |  Protein-protein Interaction Inhibitor Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Anti-Aging Natural Product Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Off-patent Drug Library  |  Mitochondrial Protection Compound Library  |  Mitochondrial Toxicity Compound Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  D-Valine-d₈  |  Antifungal agent 26  |  D-α-Hydroxyglutaric acid disodium  |  Myricetin 3-O-α-L-arabinopyranoside  |  Nicotinamide N-oxide  |  (1R,2S,7R)-Sitafloxacin-d₄ hydrochloride  |  Nebacumab  |  Deoxycholic acid-d₅  |  Doxorubicin-¹³C,d₃ TFA  |  Gepotidacin  |  Amycolatopsin A  |  PC945  |  Palitantin  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  Sulbactam-d₂ sodium  |  Adrenaline sulfate  |  Oleic acid-¹³C  |  Dextranase  |  Antimicrobial agent-5  |  NBTIs-IN-4  |  H2S Donor 5a  |  Proanthocyanidins  |  Anticancer agent 120  |  Azlocillin sodium salt  |  Chitin synthase inhibitor 11  |  Methylmalonic acid  |  Antitubercular agent-13  |  Glycine, N-(aminoiminomethyl)-N-methyl-¹³C  |  Dihydroxyacetone phosphate

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團(tuán)隊跟蹤新的制藥及生命科學(xué)研究進(jìn)展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機(jī)構(gòu)建立了長期的合作。